Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™
Go back to Enteris BioPharma's "Feasibility-to-Licensing" Partner, Cara Therapeutics, Doses First Patient in Phase 2 Trial of Peptelligence®-Engineered Oral KORSUVA™| CARA THERAPEUTICS (NASDAQ: CARA) | Delayed: 5.32 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.32 | 52 Week High | $17.69 | |||
| Open | $5.32 | 52 Week Low | $4.26 | |||
| Day High | $5.32 | P/E | N/A | |||
| Day Low | $5.32 | EPS | $-0.42 | |||
| Volume | 215 | |||||
